Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions Licenses Low-Density Microarray Technology from Affymetrix

NEW YORK, Jan 4 – Affymetrix has granted Genomic Solutions a non-exclusive license to commercialize low and medium density microarrays, the companies announced Thursday.

Under the agreement, Genomic Solutions will provide Affymetrix with fees and royalty payments on arrays it sells. Genomic Solutions plans to build upon its line of GeneMap microarrays to include human, mouse and rat array sets as well as arrays specific to diseases and biochemical pathways, a company statement said. Currently, Genomic Solutions only offers a cancer-based microarray.

" Genomic Solutions is pleased to be able to provide this license to our GeneMap array product customers,"  Shannon Richey, vice president of the genomic business unit at Genomic Solutions, said in a statement. " With this license agreement, Genomic Solutions is now well-positioned to provide a broader offering of cDNA and oligonucleotide arrays to the marketplace.

Over 25 companies have licensed array technology from Affymetrix, which holds a sizeable portion of the intellectual property in the field.   

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.